Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Sep 30, 2025	Dec 31, 2024
Selling, General & Admin	20.62	14.25
Research & Development	104.45	81.01
Operating Expenses	125.08	95.26
Operating Income	-125.08	-95.26
Interest Expense	-0.13	-1.6
Interest & Investment Income	16.85	6.4
Other Non Operating Income (Expenses)	-0.01	0
EBT Excluding Unusual Items	-108.37	-90.46
Other Unusual Items	-0.87	-0.87
Pretax Income	-109.24	-91.34
Net Income	-109.24	-91.34
Preferred Dividends & Other Adjustments	-25.67	-20.39
Net Income to Common	-83.57	-70.95
Shares Outstanding (Basic)	43	17
Shares Outstanding (Diluted)	43	17
EPS (Basic)	-1.95	-4.23
EPS (Diluted)	-1.95	-4.23
Free Cash Flow	-89.87	-63.3
Free Cash Flow Per Share	-2.09	-3.77
EBITDA	-125	-95.23
D&A For EBITDA	0.07	0.03
EBIT	-125.08	-95.26

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q